AU2007225054B2 - Diagnosis and prognosis of dipeptidyl peptidase-associated disease states - Google Patents

Diagnosis and prognosis of dipeptidyl peptidase-associated disease states Download PDF

Info

Publication number
AU2007225054B2
AU2007225054B2 AU2007225054A AU2007225054A AU2007225054B2 AU 2007225054 B2 AU2007225054 B2 AU 2007225054B2 AU 2007225054 A AU2007225054 A AU 2007225054A AU 2007225054 A AU2007225054 A AU 2007225054A AU 2007225054 B2 AU2007225054 B2 AU 2007225054B2
Authority
AU
Australia
Prior art keywords
dpp
activity
measured
portions
parameter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007225054A
Other languages
English (en)
Other versions
AU2007225054A1 (en
Inventor
Craig A. Gelfand
Patrick O'mullan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Becton Dickinson and Co
Original Assignee
Becton Dickinson and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becton Dickinson and Co filed Critical Becton Dickinson and Co
Publication of AU2007225054A1 publication Critical patent/AU2007225054A1/en
Application granted granted Critical
Publication of AU2007225054B2 publication Critical patent/AU2007225054B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
AU2007225054A 2006-03-13 2007-03-13 Diagnosis and prognosis of dipeptidyl peptidase-associated disease states Active AU2007225054B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US78192406P 2006-03-13 2006-03-13
US60/781,924 2006-03-13
US80439706P 2006-06-09 2006-06-09
US60/804,397 2006-06-09
US89276707P 2007-03-02 2007-03-02
US60/892,767 2007-03-02
PCT/US2007/006653 WO2007106595A1 (en) 2006-03-13 2007-03-13 Diagnosis and prognosis of dipeptidyl peptidase-associated disease states

Publications (2)

Publication Number Publication Date
AU2007225054A1 AU2007225054A1 (en) 2007-09-20
AU2007225054B2 true AU2007225054B2 (en) 2012-08-16

Family

ID=38265130

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007225054A Active AU2007225054B2 (en) 2006-03-13 2007-03-13 Diagnosis and prognosis of dipeptidyl peptidase-associated disease states

Country Status (11)

Country Link
US (1) US8652789B2 (https=)
EP (1) EP1994415B9 (https=)
JP (1) JP5410955B2 (https=)
KR (1) KR101376471B1 (https=)
CN (1) CN101460851B (https=)
AU (1) AU2007225054B2 (https=)
BR (1) BRPI0708900A2 (https=)
CA (1) CA2645302C (https=)
ES (1) ES2549860T3 (https=)
MX (1) MX2008011665A (https=)
WO (1) WO2007106595A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527649T3 (es) * 2007-12-10 2015-01-28 F. Hoffmann-La Roche Ag Panel de marcadores para el cáncer colorrectal
ES2533428T3 (es) * 2009-05-04 2015-04-10 F. Hoffmann-La Roche Ag Uso de DPPIV/Seprasa como un marcador para el cáncer
JP6065172B2 (ja) * 2010-10-22 2017-01-25 国立大学法人名古屋大学 微小血管障害又はその関連疾患のバイオマーカー
US20140273008A1 (en) * 2013-03-15 2014-09-18 Molecular Bioproducts, Inc. Methods to assess enzyme activity using mass spectrometric immunoassay
EP3314004A1 (en) * 2015-06-26 2018-05-02 DuPont Nutrition Biosciences ApS Aminopeptidases for protein hydrolyzates
AU2017252212B2 (en) * 2016-04-21 2023-09-07 4TEEN4 Pharmaceuticals GmbH Methods for determining DPP3 and therapeutic methods
CN110426518A (zh) * 2019-07-19 2019-11-08 宁波熙宁检测技术有限公司 一种定量检测人类血浆中dpp-4酶活性的方法
EP4308937B1 (en) * 2021-03-16 2026-02-04 Astrazeneca AB System and method for online detection of a post-translational modification of a polypeptide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004104216A2 (en) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900662A (en) 1987-07-21 1990-02-13 International Immunoassay Laboratories, Inc. CK-MM myocardial infarction immunoassay
US5382515A (en) 1987-07-21 1995-01-17 International Immunoassay Laboratories, Inc. Creative kinase-MB immunoassay for myocardial infarction and reagents
US5382522A (en) 1987-07-21 1995-01-17 International Immunoassay Laboratories, Inc. Immunoassay for creatine kinase-MB and creatine kinase-BB isoforms and reagents
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004104216A2 (en) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ISHII NAOHITO ET AL ENZYME PROTEIN, 1994., Vol. 95, No. 48, pages 174-182 *
MANNUCCI E ET Al: DIABETOlOGIA, 2005., Vol. 48, No. 6, pages 1168-1172 *

Also Published As

Publication number Publication date
JP2009529884A (ja) 2009-08-27
AU2007225054A1 (en) 2007-09-20
CA2645302A1 (en) 2007-09-20
US8652789B2 (en) 2014-02-18
EP1994415B9 (en) 2015-12-16
ES2549860T3 (es) 2015-11-02
KR101376471B1 (ko) 2014-03-27
CA2645302C (en) 2017-07-11
JP5410955B2 (ja) 2014-02-05
CN101460851B (zh) 2016-09-21
EP1994415B1 (en) 2015-07-29
WO2007106595A1 (en) 2007-09-20
MX2008011665A (es) 2008-10-08
KR20090008218A (ko) 2009-01-21
EP1994415A1 (en) 2008-11-26
US20070264671A1 (en) 2007-11-15
CN101460851A (zh) 2009-06-17
BRPI0708900A2 (pt) 2011-06-14

Similar Documents

Publication Publication Date Title
AU2007225054B2 (en) Diagnosis and prognosis of dipeptidyl peptidase-associated disease states
Lahiri et al. Systemic inflammatory response syndrome after major abdominal surgery predicted by early upregulation of TLR4 and TLR5
Ghallab et al. Serum and salivary levels of chemerin and MMP-9 in oral squamous cell carcinoma and oral premalignant lesions
Morgan et al. Role of arterial telomere dysfunction in hypertension: relative contributions of telomere shortening and telomere uncapping
Yang et al. 5-Hydroxymethylcytosines in circulating cell-free DNA reveal vascular complications of type 2 diabetes
US20190264283A1 (en) URINE EXOSOME mRNAS AND METHODS OF USING SAME TO DETECT DIABETIC NEPHROPATHY
JP2002131322A5 (https=)
JP6847972B2 (ja) 大腸がん診断用組成物と診断マーカー検出方法
Trenchevska et al. Mass spectrometric immunoassay for quantitative determination of protein biomarker isoforms
Koh et al. Single cell transcriptomes derived from human cervical and uterine tissue during pregnancy
Jimbo et al. Placenta increta: postpartum monitoring of plasma cell-free fetal DNA
Hsieh et al. Circulating epithelial cell enumeration facilitates the identification and follow-up of a patient with early stage papillary thyroid microcarcinoma: A case report
Balistreri et al. The role of inflammation in type A aortic dissection: a pilot study
RU2000119129A (ru) Молекула днк, кодирующая мутантный препронейропептид y, мутантный сигнальный пептид и их применения
Simmer et al. Kallikrein 4 is a secreted protein
US20190316202A1 (en) Dna methylation in inflammatory disease
Abdulraheem et al. Diagnostic value of Interleukin-40 and Interleukin-41 for Diabetic Kidney Disease and Diabetes
Koch et al. Highly multiplexed detection of microRNAs, proteins and small molecules using barcoded molecular probes and nanopore sequencing
Hyodo et al. Molar DNA in maternal serum in a case of 46, XY heterozygous complete hydatidiform mole coexisting with a 46, XX twin live fetus
Baviera et al. Midtrimester amniotic fluid adiponectin in normal pregnancy
Jankowski et al. Biomarkers identifying deterioration of kidney graft function—usefulness of “liquid biopsy”
US7759086B2 (en) Diagnostic method for chronic fatigue syndrome by measuring elastase
Chauhan et al. Spot Urine Protein to Creatinine Ratio in Patients with Urinary Tract Infection
Kalpidis Role of Salivary Biomarkers in Diagnosis and Monitoring of Patients with Autoimmune Diseases: A Systematic Review
WO2023115171A1 (pt) Método, painel e kit para o diagnóstico e monitoramento do tratamento de pacientes com câncer de mama

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)